Treatment trajectories in urologic cancers
Longitudinal evaluation of urologic cancer treatment landscape, toxicity, and molecular testing: a decade of real-world evidence Principal Investigator : Dr. Alice DragomirInstitution: McGill University Health Centre (MUHC)Sponsor: PROVEM Scientific background Urologic cancers, including prostate, bladder, and kidney cancers, represent a substantial portion of the oncology burden in Canada. Over the past decade, their management has […]
Impact of innovations in oncology in Quebec
Evaluating the impact of therapeutic and diagnostic innovations in oncology on care trajectories and healthcare resource utilization in Quebec: A population-based study using administrative data Principal Investigator: Dr. Alice DragomirInstitution: Université de MontréalSponsor: PROVEM Scientific background Over the past two decades, oncology has undergone major transformation driven by the emergence of precision medicine, the introduction […]
PROMS and clinical trajectories in oncology
Integrating Patient-Reported Outcomes (PROMs) and Clinical Data to Advance Real-World Evidence in Oncology Principal Investigator: Sylvie LambertInstitution: Centre de recherche de l’Hôpital St-Mary’sSponsor: PROVEM Scientific background Randomized clinical trials remain the cornerstone for evaluating the efficacy of anticancer treatments. However, these studies are conducted under controlled conditions and often involve selected patient populations, which limits […]